FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2316976114> ?p ?o ?g. }

• W2316976114 endingPage "374" @default.
• W2316976114 startingPage "366" @default.
• W2316976114 abstract "Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) plays a central role in glycolysis. Because cancer cells rely on aerobic glycolysis rather than oxidative phosphorylation, GAPDH-depleting agents have a therapeutic potential to impede cancer cell proliferation. Knockdown of GAPDH by RNA interference induced the accelerated senescent phenotype in A549 cells, suggesting that GAPDH is a potential molecular target for combination chemotherapy. The cytotoxic effects of a panel of anticancer drugs, 5-fluorouracil, 5-fluorouridine, 5-fluorodeoxyuridine, 6-thioguanine, cytarabine, fludarabine, cladribine, clofarabine, 2-chloroadenosine, and doxorubicin, were assessed in GAPDH-depleted A549 cells using a cell proliferation assay. GAPDH-depleted A549 cells, when compared with control cells, exhibited increased chemoresistance to several antimetabolite agents including cytarabine [inhibitory concentration 50 (IC50) 1.7±0.3 vs. 0.03±0.02 μmol/l], 2-chloroadenosine (IC50 7.1±1.8 vs. 1.5±0.6 μmol/l), 6-thioguanine (IC50 7.5±1.6 vs. 1.4±0.5 μmol/l), 5-fluorouracil (IC50 13.2±2.5 vs. 3.0±0.7 μmol/l), and 5-fluorodeoxyuridine (IC50 >100 vs. 3.7±0.9 μmol/l), which we designated as group A agents. In contrast, GAPDH-deficient and GAPDH-proficient cells were equally sensitive to group B agents including doxorubicin (IC50 0.05±0.02 vs. 0.04±0.02 μmol/l), fludarabine (IC50 18.5±2.3 vs. 15.7±2.8 μmol/l), 5-fluorouridine (IC50 0.1±0.03 vs. 0.1±0.03 μmol/l), clofarabine (IC50 0.7±0.3 vs. 0.5±0.3 μmol/l), and cladribine (IC50 0.5±0.1 vs. 0.5±0.2 μmol/l). After treatment with group B agents at concentrations equivalent to 7-10-fold the IC50 value, the fraction of apoptotic cells in GAPDH-depleted, senescent A549 cells was similar to that in GAPDH-proficient cells. Our study identified the antimetabolite drugs active in senescent cells that can be used in combination with GAPDH inhibitors in cancer treatment. GAPDH-targeted combination therapy is a novel strategy to control the proliferation of tumor cells." @default.
• W2316976114 created "2016-06-24" @default.
• W2316976114 creator A5009358670 @default.
• W2316976114 creator A5036222375 @default.
• W2316976114 creator A5041826636 @default.
• W2316976114 date "2013-04-01" @default.
• W2316976114 modified "2023-09-27" @default.
• W2316976114 title "Cytotoxicity of chemotherapeutic agents in glyceraldehyde-3-phosphate dehydrogenase-depleted human lung carcinoma A549 cells with the accelerated senescence phenotype" @default.
• W2316976114 cites W121485390 @default.
• W2316976114 cites W1963779075 @default.
• W2316976114 cites W1964922758 @default.
• W2316976114 cites W1991064992 @default.
• W2316976114 cites W1995570857 @default.
• W2316976114 cites W2039758055 @default.
• W2316976114 cites W2040233505 @default.
• W2316976114 cites W2044041384 @default.
• W2316976114 cites W2056250383 @default.
• W2316976114 cites W2062865409 @default.
• W2316976114 cites W2077450385 @default.
• W2316976114 cites W2083532816 @default.
• W2316976114 cites W2130744509 @default.
• W2316976114 cites W2135291490 @default.
• W2316976114 cites W2136380412 @default.
• W2316976114 cites W2155951732 @default.
• W2316976114 cites W2344697213 @default.
• W2316976114 cites W2416753637 @default.
• W2316976114 cites W4256601499 @default.
• W2316976114 doi "https://doi.org/10.1097/cad.0b013e32835e3378" @default.
• W2316976114 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23377192" @default.
• W2316976114 hasPublicationYear "2013" @default.
• W2316976114 type Work @default.
• W2316976114 sameAs 2316976114 @default.
• W2316976114 citedByCount "8" @default.
• W2316976114 countsByYear W23169761142014 @default.
• W2316976114 countsByYear W23169761142015 @default.
• W2316976114 countsByYear W23169761142017 @default.
• W2316976114 countsByYear W23169761142020 @default.
• W2316976114 countsByYear W23169761142022 @default.
• W2316976114 crossrefType "journal-article" @default.
• W2316976114 hasAuthorship W2316976114A5009358670 @default.
• W2316976114 hasAuthorship W2316976114A5036222375 @default.
• W2316976114 hasAuthorship W2316976114A5041826636 @default.
• W2316976114 hasConcept C121608353 @default.
• W2316976114 hasConcept C134792803 @default.
• W2316976114 hasConcept C153911025 @default.
• W2316976114 hasConcept C181199279 @default.
• W2316976114 hasConcept C185592680 @default.
• W2316976114 hasConcept C190283241 @default.
• W2316976114 hasConcept C202751555 @default.
• W2316976114 hasConcept C2776317432 @default.
• W2316976114 hasConcept C2776694085 @default.
• W2316976114 hasConcept C2776755627 @default.
• W2316976114 hasConcept C2777198975 @default.
• W2316976114 hasConcept C2777318727 @default.
• W2316976114 hasConcept C2777752497 @default.
• W2316976114 hasConcept C2778041864 @default.
• W2316976114 hasConcept C2778239845 @default.
• W2316976114 hasConcept C2778729363 @default.
• W2316976114 hasConcept C2779263901 @default.
• W2316976114 hasConcept C2780962732 @default.
• W2316976114 hasConcept C2781303535 @default.
• W2316976114 hasConcept C502942594 @default.
• W2316976114 hasConcept C526805850 @default.
• W2316976114 hasConcept C54355233 @default.
• W2316976114 hasConcept C55493867 @default.
• W2316976114 hasConcept C81729549 @default.
• W2316976114 hasConcept C86803240 @default.
• W2316976114 hasConcept C96232424 @default.
• W2316976114 hasConcept C98274493 @default.
• W2316976114 hasConceptScore W2316976114C121608353 @default.
• W2316976114 hasConceptScore W2316976114C134792803 @default.
• W2316976114 hasConceptScore W2316976114C153911025 @default.
• W2316976114 hasConceptScore W2316976114C181199279 @default.
• W2316976114 hasConceptScore W2316976114C185592680 @default.
• W2316976114 hasConceptScore W2316976114C190283241 @default.
• W2316976114 hasConceptScore W2316976114C202751555 @default.
• W2316976114 hasConceptScore W2316976114C2776317432 @default.
• W2316976114 hasConceptScore W2316976114C2776694085 @default.
• W2316976114 hasConceptScore W2316976114C2776755627 @default.
• W2316976114 hasConceptScore W2316976114C2777198975 @default.
• W2316976114 hasConceptScore W2316976114C2777318727 @default.
• W2316976114 hasConceptScore W2316976114C2777752497 @default.
• W2316976114 hasConceptScore W2316976114C2778041864 @default.
• W2316976114 hasConceptScore W2316976114C2778239845 @default.
• W2316976114 hasConceptScore W2316976114C2778729363 @default.
• W2316976114 hasConceptScore W2316976114C2779263901 @default.
• W2316976114 hasConceptScore W2316976114C2780962732 @default.
• W2316976114 hasConceptScore W2316976114C2781303535 @default.
• W2316976114 hasConceptScore W2316976114C502942594 @default.
• W2316976114 hasConceptScore W2316976114C526805850 @default.
• W2316976114 hasConceptScore W2316976114C54355233 @default.
• W2316976114 hasConceptScore W2316976114C55493867 @default.
• W2316976114 hasConceptScore W2316976114C81729549 @default.
• W2316976114 hasConceptScore W2316976114C86803240 @default.
• W2316976114 hasConceptScore W2316976114C96232424 @default.
• W2316976114 hasConceptScore W2316976114C98274493 @default.
• W2316976114 hasIssue "4" @default.
• W2316976114 hasLocation W23169761141 @default.

• next